Canada
· Delayed Price · Currency is CAD PharmaCielo Statistics
Total Valuation
PharmaCielo has a market cap or net worth of CAD 11.42 million. The enterprise value is 31.80 million.
| Market Cap | 11.42M |
| Enterprise Value | 31.80M |
Important Dates
The next estimated earnings date is Thursday, May 29, 2025.
| Earnings Date | May 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaCielo has 175.72 million shares outstanding. The number of shares has increased by 6.83% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 175.72M |
| Shares Change (YoY) | +6.83% |
| Shares Change (QoQ) | +8.17% |
| Owned by Insiders (%) | 8.54% |
| Owned by Institutions (%) | 4.58% |
| Float | 160.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.19 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.48 |
| EV / Sales | 9.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.06 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -14.33% |
| Return on Invested Capital (ROIC) | -19.68% |
| Return on Capital Employed (ROCE) | 164.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.41% in the last 52 weeks. The beta is 2.20, so PharmaCielo's price volatility has been higher than the market average.
| Beta (5Y) | 2.20 |
| 52-Week Price Change | -63.41% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 47.51 |
| Average Volume (20 Days) | 351,387 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaCielo had revenue of CAD 3.48 million and -9.14 million in losses. Loss per share was -0.05.
| Revenue | 3.48M |
| Gross Profit | 730,878 |
| Operating Income | -4.67M |
| Pretax Income | -9.14M |
| Net Income | -9.14M |
| EBITDA | -4.53M |
| EBIT | -4.67M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 147,939 in cash and 20.52 million in debt, giving a net cash position of -20.38 million or -0.12 per share.
| Cash & Cash Equivalents | 147,939 |
| Total Debt | 20.52M |
| Net Cash | -20.38M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | -7.52M |
| Book Value Per Share | -0.04 |
| Working Capital | -18.80M |
Cash Flow
| Operating Cash Flow | -1.97M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 21.00%, with operating and profit margins of -134.06% and -262.70%.
| Gross Margin | 21.00% |
| Operating Margin | -134.06% |
| Pretax Margin | -262.70% |
| Profit Margin | -262.70% |
| EBITDA Margin | -130.12% |
| EBIT Margin | -134.06% |
| FCF Margin | n/a |
Dividends & Yields
PharmaCielo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.83% |
| Shareholder Yield | -6.83% |
| Earnings Yield | -80.03% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on January 18, 2019. It was a reverse split with a ratio of 0.083752.
| Last Split Date | Jan 18, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.083752 |
Scores
PharmaCielo has an Altman Z-Score of -17.12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.12 |
| Piotroski F-Score | n/a |